NASH - Nonalcoholic Steatohepatitis
121
12
24
53
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
25 trials with published results (21%)
Research Maturity
53 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.1%
11 terminated out of 121 trials
82.8%
-3.7% vs benchmark
9%
11 trials in Phase 3/4
47%
25 of 53 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 53 completed trials
Clinical Trials (121)
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Tocotrienol Against the Progression of End Stage Liver Disease
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
Statins for the Treatment of NASH
Nonalcoholic Fatty Liver Disease in HIV Database
Hepatic Energy Fluxes in NASH and NAS Patients
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)